Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Segura, Sonia Jaramillo; Wass, Maxi; Schaffrath, Judith; Rieger, Kathrin; Nogai, Axel; Haenel, Mathias; Herbst, Regina; Stoelzel, Friedrich; Röllig, Christoph; Jost, Edgar; Schlenk, Richard F.; Noppeney, Richard; Brandts, Christian; Krug, Utz; Goetze, Katharina; Buske, Sebastian; Florschütz, Axel; Schubert, Jörg; Opitz, Bernhard; Mohren, Martin; Eßeling, Eva; Witzendorff, Stephan von; Subklewe, Marion; Kaufmann, Martin; Frickhofen, N; Schölz, Christian; Schäfer‐Eckart, Kerstin; Kunzmann, Volker; Schmidt‐Hieber, Martin; Sayer, Herbert G.; Rank, Andreas; Hemmati, Philipp; Schueler, Frank; Kowoll, Simone; Scheller, Marina; Steighardt, Jörg; Edemir, Bayram; Mueller, Lutz Peter; Gliko-Kabir, Irit; Ludwig-Kraus, Beatrice; Edemir, Sabine; Sorani, Ella; Binder, Mascha; Vainstein, Abi; Kadosh, Shaul; Gromann, Cora; Wienke, Andreas; Baldus, Claudia D.; Platzbecker, Uwe; Bornhaeuser, Martin; Junghanß, Christian; Müller-Tidow, Carsten

doi:10.1182/blood-2022-166748

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The completed study (NCT01838395) revealed higher CR rates than cytarabine alone in comparison to previous studies and good tolerability 73 . Recently, another clinical trial evaluated BL‐8040 in combination with cytarabine for consolidation therapy in AML in the first remission 74 . Progression‐free survival and overall survival were not improved by the addition of BL‐8040 and increased toxicity was observed.…”

Section: Targeted Therapies Interacting With the Modified Niche In Amlmentioning

confidence: 93%

“…73 Recently, another clinical trial evaluated BL-8040 in combination with cytarabine for consolidation therapy in AML in the first remission. 74 Progression-free survival and overall survival were not improved by the addition of BL-8040 and increased toxicity was observed. Ongoing translational analyses may shed light on the underlying mechanisms.…”

Section: Therapies Targeting Sfm-drmentioning

confidence: 97%

See 1 more Smart Citation

The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia

Allert

Müller‐Tidow

Blank

2023

Intl Journal of Cancer

View full text Add to dashboard Cite

The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives rise to altered metabolic states and activates signaling pathways which lead to resistance and impede effective therapy. Therefore, the underlying processes and mechanisms represent attractive therapeutic leverage points for overcoming therapy resistance in AML. Here, we briefly discuss resistance mechanisms based on cell interactions and secreted soluble factors in the hematopoietic niche and provide an overview of niche‐related therapeutic targets currently undergoing preclinical and clinical investigation which may help improve the outcome in AML therapy.

show abstract

Section: Targeted Therapies Interacting With the Modified Niche In Amlmentioning

confidence: 93%

Section: Therapies Targeting Sfm-drmentioning

confidence: 97%

The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia

Allert

Müller‐Tidow

Blank

2023

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

Motixafortide: First Approval

Hoy

2023

Drugs

View full text Add to dashboard Cite

A selective CXCR4 inhibitor being developed by BioLineRx under licence from Biokine Therapeutics for HSC mobilization and the treatment of various cancers • Received its first approval on 11 September 2023 in the USA • Approved for use in combination with filgrastim (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online.

show abstract

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Cited by 2 publications

References 0 publications

The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia

The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia

Motixafortide: First Approval

Contact Info

Product

Resources

About